REPORT ID 13820

United States Capecitabine Market Report 2017

Publish Date
22-Nov-17
Pages
100
Format
Electronic (PDF)

In this report, the United States Capecitabine market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report splits the United States market into seven regions:
    The West
    Southwest
    The Middle Atlantic
    New England
    The South
    The Midwest
with sales (volume), revenue (value), market share and growth rate of Capecitabine in these regions, from 2012 to 2022 (forecast).

United States Capecitabine market competition by top manufacturers/players, with Capecitabine sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including
    Roche
    Teva
    Mylan
    Hikma
    Hengrui Medicine
    Cipla
    Reliance Group
    Hetero

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
    500 mg
    150 mg
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
    Breast Cancer
    Colorectal cancer
    Stomach Cancer

If you have any special requirements, please let us know and we will offer you the report as you want.

 
			   
Table of Contents

United States Capecitabine Market Report 2017
1 Capecitabine Overview
    1.1 Product Overview and Scope of Capecitabine
    1.2 Classification of Capecitabine by Product Category
        1.2.1 United States Capecitabine Market Size (Sales Volume) Comparison by Type (2012-2022)
        1.2.2 United States Capecitabine Market Size (Sales Volume) Market Share by Type (Product Category) in 2016
        1.2.3 500 mg
        1.2.4 150 mg
    1.3 United States Capecitabine Market by Application/End Users
        1.3.1 United States Capecitabine Market Size (Consumption) and Market Share Comparison by Application (2012-2022)
        1.3.2 Breast Cancer
        1.3.3 Colorectal cancer
        1.3.4 Stomach Cancer
    1.4 United States Capecitabine Market by Region
        1.4.1 United States Capecitabine Market Size (Value) Comparison by Region (2012-2022)
        1.4.2 The West Capecitabine Status and Prospect (2012-2022)
        1.4.3 Southwest Capecitabine Status and Prospect (2012-2022)
        1.4.4 The Middle Atlantic Capecitabine Status and Prospect (2012-2022)
        1.4.5 New England Capecitabine Status and Prospect (2012-2022)
        1.4.6 The South Capecitabine Status and Prospect (2012-2022)
        1.4.7 The Midwest Capecitabine Status and Prospect (2012-2022)
    1.5 United States Market Size (Value and Volume) of Capecitabine (2012-2022)
        1.5.1 United States Capecitabine Sales and Growth Rate (2012-2022)
        1.5.2 United States Capecitabine Revenue and Growth Rate (2012-2022)

2 United States Capecitabine Market Competition by Players/Suppliers
    2.1 United States Capecitabine Sales and Market Share of Key Players/Suppliers (2012-2017)
    2.2 United States Capecitabine Revenue and Share by Players/Suppliers (2012-2017)
    2.3 United States Capecitabine Average Price by Players/Suppliers (2012-2017)
    2.4 United States Capecitabine Market Competitive Situation and Trends
        2.4.1 United States Capecitabine Market Concentration Rate
        2.4.2 United States Capecitabine Market Share of Top 3 and Top 5 Players/Suppliers
        2.4.3 Mergers & Acquisitions, Expansion in United States Market
    2.5 United States Players/Suppliers Capecitabine Manufacturing Base Distribution, Sales Area, Product Type

3 United States Capecitabine Sales (Volume) and Revenue (Value) by Region (2012-2017)
    3.1 United States Capecitabine Sales and Market Share by Region (2012-2017)
    3.2 United States Capecitabine Revenue and Market Share by Region (2012-2017)
    3.3 United States Capecitabine Price by Region (2012-2017)

4 United States Capecitabine Sales (Volume) and Revenue (Value) by Type (Product Category) (2012-2017)
    4.1 United States Capecitabine Sales and Market Share by Type (Product Category) (2012-2017)
    4.2 United States Capecitabine Revenue and Market Share by Type (2012-2017)
    4.3 United States Capecitabine Price by Type (2012-2017)
    4.4 United States Capecitabine Sales Growth Rate by Type (2012-2017)

5 United States Capecitabine Sales (Volume) by Application (2012-2017)
    5.1 United States Capecitabine Sales and Market Share by Application (2012-2017)
    5.2 United States Capecitabine Sales Growth Rate by Application (2012-2017)
    5.3 Market Drivers and Opportunities

6  United States Capecitabine Players/Suppliers Profiles and Sales Data
    6.1 Roche
        6.1.1 Company Basic Information, Manufacturing Base and Competitors
        6.1.2 Capecitabine Product Category, Application and Specification
            6.1.2.1 Product A
            6.1.2.2 Product B
        6.1.3 Roche Capecitabine Sales, Revenue, Price and Gross Margin (2012-2017)
        6.1.4 Main Business/Business Overview
    6.2 Teva
        6.2.2 Capecitabine Product Category, Application and Specification
            6.2.2.1 Product A
            6.2.2.2 Product B
        6.2.3 Teva Capecitabine Sales, Revenue, Price and Gross Margin (2012-2017)
        6.2.4 Main Business/Business Overview
    6.3 Mylan
        6.3.2 Capecitabine Product Category, Application and Specification
            6.3.2.1 Product A
            6.3.2.2 Product B
        6.3.3 Mylan Capecitabine Sales, Revenue, Price and Gross Margin (2012-2017)
        6.3.4 Main Business/Business Overview
    6.4 Hikma
        6.4.2 Capecitabine Product Category, Application and Specification
            6.4.2.1 Product A
            6.4.2.2 Product B
        6.4.3 Hikma Capecitabine Sales, Revenue, Price and Gross Margin (2012-2017)
        6.4.4 Main Business/Business Overview
    6.5 Hengrui Medicine
        6.5.2 Capecitabine Product Category, Application and Specification
            6.5.2.1 Product A
            6.5.2.2 Product B
        6.5.3 Hengrui Medicine Capecitabine Sales, Revenue, Price and Gross Margin (2012-2017)
        6.5.4 Main Business/Business Overview
    6.6 Cipla
        6.6.2 Capecitabine Product Category, Application and Specification
            6.6.2.1 Product A
            6.6.2.2 Product B
        6.6.3 Cipla Capecitabine Sales, Revenue, Price and Gross Margin (2012-2017)
        6.6.4 Main Business/Business Overview
    6.7 Reliance Group
        6.7.2 Capecitabine Product Category, Application and Specification
            6.7.2.1 Product A
            6.7.2.2 Product B
        6.7.3 Reliance Group Capecitabine Sales, Revenue, Price and Gross Margin (2012-2017)
        6.7.4 Main Business/Business Overview
    6.8 Hetero
        6.8.2 Capecitabine Product Category, Application and Specification
            6.8.2.1 Product A
            6.8.2.2 Product B
        6.8.3 Hetero Capecitabine Sales, Revenue, Price and Gross Margin (2012-2017)
        6.8.4 Main Business/Business Overview

7 Capecitabine Manufacturing Cost Analysis
    7.1 Capecitabine Key Raw Materials Analysis
        7.1.1 Key Raw Materials
        7.1.2 Price Trend of Key Raw Materials
        7.1.3 Key Suppliers of Raw Materials
        7.1.4 Market Concentration Rate of Raw Materials
    7.2 Proportion of Manufacturing Cost Structure
        7.2.1 Raw Materials
        7.2.2 Labor Cost
        7.2.3 Manufacturing Expenses
    7.3 Manufacturing Process Analysis of Capecitabine

8 Industrial Chain, Sourcing Strategy and Downstream Buyers
    8.1 Capecitabine Industrial Chain Analysis
    8.2 Upstream Raw Materials Sourcing
    8.3 Raw Materials Sources of Capecitabine Major Manufacturers in 2016
    8.4 Downstream Buyers

9 Marketing Strategy Analysis, Distributors/Traders
    9.1 Marketing Channel
        9.1.1 Direct Marketing
        9.1.2 Indirect Marketing
        9.1.3 Marketing Channel Development Trend
    9.2 Market Positioning
        9.2.1 Pricing Strategy
        9.2.2 Brand Strategy
        9.2.3 Target Client
    9.3 Distributors/Traders List

10 Market Effect Factors Analysis
    10.1 Technology Progress/Risk
        10.1.1 Substitutes Threat
        10.1.2 Technology Progress in Related Industry
    10.2 Consumer Needs/Customer Preference Change
    10.3 Economic/Political Environmental Change

11 United States Capecitabine Market Size (Value and Volume) Forecast (2017-2022)
    11.1 United States Capecitabine Sales Volume, Revenue Forecast (2017-2022)
    11.2 United States Capecitabine Sales Volume Forecast by Type (2017-2022)
    11.3 United States Capecitabine Sales Volume Forecast by Application (2017-2022)
    11.4 United States Capecitabine Sales Volume Forecast by Region (2017-2022)

12 Research Findings and Conclusion

13 Appendix
    13.1 Methodology/Research Approach
        13.1.1 Research Programs/Design
        13.1.2 Market Size Estimation
        13.1.3 Market Breakdown and Data Triangulation
    13.2 Data Source
        13.2.1 Secondary Sources
        13.2.2 Primary Sources
    13.3 Disclaimer